kw-6356
Small moleculeexperimental
Clinical trial activity
8 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2016 (NCT02939391)
Timeline
Indications
Mechanism of action
- Adenosine A2a receptorINHIBITOR
ADORA2A inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- kw-6356
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04342273 | Phase 1 | Mar 31, 2020 | Kyowa Hakko Kirin |
| NCT04190654 | Phase 1 | Nov 26, 2019 | Kyowa Kirin |
| NCT04070495 | Phase 1 | Aug 31, 2019 | Kyowa Hakko Kirin |
| NCT04147910 | Phase 1 | Aug 21, 2019 | Kyowa Kirin |
| NCT03970798 | Phase 1 | May 22, 2019 | Kyowa Hakko Kirin |
| NCT03830528 | Phase 1 | Feb 26, 2019 | Kyowa Hakko Kirin |
| NCT03703570 | Phase 2 | Sep 29, 2018 | Kyowa Hakko Kirin |
| NCT02939391 | Phase 2 | Sep 1, 2016 | Kyowa Hakko Kirin |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kyowa Hakko Kirin | For profit | 6 | 6 | 2 | 2016 |
| Kyowa Kirin | For profit | 2 | 2 | 1 | 2019 |
2 organizations
Page 1 / 1